BBI - BBI STOCK NEWS

Brickell Biotech, Inc. (Nasdaq: BBI) announced a public offering of 26,316,000 shares of common stock priced at $0.38 per share, expected to raise approximately $10.0 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 3,947,400 shares. The funds will be allocated for research and development, clinical trials, and general corporate purposes. The offering is set to close on November 1, 2021, subject to customary conditions.

Brickell Biotech, Inc. (Nasdaq: BBI) has initiated an underwritten public offering of its common stock, aiming to grant underwriters a 30-day option to purchase an additional 15% of shares at the offering price. The net proceeds will be allocated towards research, clinical trials, and general corporate purposes. The offering is contingent on market conditions and is conducted under an effective registration statement with the SEC. William Blair & Company and Oppenheimer & Co. are the joint book-running managers for this offering.

Brickell Biotech (BBI) announced positive results from its Phase 3 studies for sofpironium bromide gel, 15%, demonstrating significant efficacy in patients with primary axillary hyperhidrosis. The studies, Cardigan I and II, involved over 700 participants and showed that the gel led to a meaningful improvement in sweating symptoms. Looking ahead, Brickell plans to submit a New Drug Application (NDA) to the FDA by mid-2022. The treatment was well-tolerated with a majority of participants completing the study, showing promise as a first-line therapy for hyperhidrosis.

Brickell Biotech (Nasdaq: BBI) announced a KOL webinar on September 24, 2021, at 10:00 a.m. EDT to discuss DYRK1A's role in autoimmune diseases. Dr. Bernard Khor from Benaroya Research Institute will present the latest findings on this target and its therapeutic potential. Brickell's management will offer updates on their investigational DYRK1A inhibitor platform, particularly the Phase 1-ready BBI-02, aimed at treating autoimmune diseases like atopic dermatitis and rheumatoid arthritis. The webinar will be available on their website, with a replay accessible post-event.

Brickell Biotech, Inc. (Nasdaq: BBI), a clinical-stage pharmaceutical company, will participate in two virtual investment conferences: the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15 and Lake Street Partners 5th Annual Best Ideas Growth Conference from September 14-15. CEO Robert Brown will present at the H.C. Wainwright conference starting at 7:00 a.m. ET on September 13. Management will also conduct virtual 1-on-1 meetings throughout the events. Brickell focuses on innovative therapeutics for dermatologic and autoimmune diseases.

Brickell Biotech has appointed Dr. Monica Luchi as Chief Medical Officer, bringing over 20 years of experience in drug development.

Dr. Luchi's role will focus on clinical strategy and medical affairs, particularly in the company's pipeline expansion for autoimmune diseases.

CEO Robert Brown emphasized her expertise as critical for accelerating the development of their DYRK1A inhibitor platform and upcoming clinical trials, including the Phase 3 data for sofpironium bromide gel, 15%.

Dr. Luchi previously held significant roles in various biopharmaceutical companies, enhancing Brickell's position in the market.

Brickell Biotech has entered a definitive agreement with Voronoi Inc. to acquire exclusive rights to develop a novel DYRK1A inhibitor platform targeting autoimmune and inflammatory diseases. The lead program, BBI-02, is set to enter Phase 1 clinical trials in 2022, promising a new, effective treatment option. The agreement involves a total payment of $5 million, with additional milestone payments up to $318.5 million. This move is anticipated to enhance Brickell's portfolio and patient impact significantly.

Brickell Biotech (Nasdaq: BBI) announces the completion of patient visits in the Phase 3 Cardigan studies evaluating sofpironium bromide gel, 15% for primary axillary hyperhidrosis. Topline results are expected in Q4 2021, with a New Drug Application (NDA) submission anticipated in mid-2022, subject to study outcomes. The Cardigan studies involve approximately 700 participants, assessing efficacy and safety through various endpoints, including sweat production and patient-reported outcomes. Sofpironium bromide gel, 5% is already approved in Japan.

Brickell Biotech (Nasdaq: BBI) announced significant progress in its clinical programs for sofpironium bromide gel, with the final patient completing the Phase 3 Cardigan I study and enrollment finished for Cardigan II. Topline results from both studies are expected in Q4 2021. A recent capital raise of $8.1 million will fund operations beyond a potential NDA submission in mid-2022. Financially, Brickell reported a net loss of $11.1 million for Q2 2021 and $0.2 million in revenue, driven mainly by royalty revenue from Japan.